Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Risk for Use of Antidepressants, Anxiolytics and Hypnotics in Parents of Children Diagnosed with Cancer: A Population-Based Cohort Study
29 Pages Posted: 2 Aug 2018
More...Abstract
Background: Experiencing cancer in a child may be stressful for the whole family. In a population-based cohort study, we investigated the psychological impact in terms of risk of psychotropic medication in the parents.
Methods: We examined the risk for first prescription of psychotropic medication (antidepressants, anxiolytics, or hypnotics) among all parents of children with cancer (N=6744) identified in the Danish Cancer Registry between 1998-2014 using matched parents of cancer-free children (N=65 421) as a comparison cohort. In Cox proportional hazard models, we estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for first prescription of psychotropic medication according to cancer status in the child. Further, to identify potential vulnerable sub-groups among parents of children with cancer, we followed all parents of children with cancer identified in the Childhood Cancer Registry between 2003-2015 (N = 3290 parents) and estimated HRs for first prescription of psychotropic medication according to education, income, cancer type, cancer relapse or death of the child.
Findings: Three years after diagnosis, parents of children with cancer had a 14% cumulative incidence (95% CI 13·6-15·3) of having a first prescription of any psychotropic medication compared to 10 % in of parents of cancer-free children. The risk was highest in the first year and was particularly high for anxiolytics (HR 2·99 CI 2·54-3·52) and hypnotics (HR 2·64 CI 2·26-3·09). Among parents of children with cancer, the highest risk was seen for hypnotics in parents who experienced the death of a child (HR 6·91 CI, 3·50-13·66) in the first year after diagnosis, but an increased risk was also seen according to relapse, education, and income.
Interpretation: Increased use of psychotropic drugs among parents to children with cancer emphasizes the need for psychological support to prevent psychiatric morbidity so severe as to require medical treatment.
Funding: Danish Childhood Cancer Foundation.
Conflict of Interests: The authors declare no potential conflict of interest.
Ethical Approval Statement: The study approved by the Danish Data protection Agency (No. 2014-41-3405). Research based solely on registry data are exempt from ethical approval as well as from informed consent according to Danish law.
Keywords: antidepressants, anxiolytics, hypnotics, psychotropic medicine, childhood cancer, parents, cohort study, distress
Suggested Citation: Suggested Citation